Immunoadsorption and subsequent immunoglobulin G replacement (IA/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis - Takeaways - MDSpire

Immunoadsorption and subsequent immunoglobulin G replacement (IA/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis

  • By

  • Xiao Xia

  • Yuhao Yao

  • Jun Li

  • Shiyi Tao

  • Xuanchun Huang

  • Chao Meng

  • Yiying Liu

  • Yonghao Li

  • Ruikang Liu

  • June 23, 2026

  • 0 min

Share

  • 1

    Dilated cardiomyopathy (DCM) is a significant cause of morbidity and mortality, with a global prevalence of approximately 3.2 million cases.

  • 2

    Immunoadsorption combined with immunoglobulin G replacement therapy (IA/IG) has shown potential in improving cardiac function in DCM patients.

  • 3

    The systematic review included 18 studies with 809 participants, demonstrating significant improvements in left ventricular ejection fraction and other cardiac parameters.

  • 4

    IA/IG therapy resulted in a mean difference of 7.71% in left ventricular ejection fraction, indicating a notable improvement from baseline.

  • 5

    The study emphasizes the need for further high-quality, large-scale trials to confirm the long-term benefits of IA/IG therapy in DCM.

Original Source(s)

Immunoadsorption and subsequent immunoglobulin G replacement (IA/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis

  • by Xiao Xia, Yuhao Yao, Jun Li, Shiyi Tao, Xuanchun Huang, Chao Meng, Yiying Liu, Yonghao Li, Ruikang Liu

  • June 23, 2026

Related Content

Perioperative anesthetic management in pediatric heart transplantation: a single-center descriptive study involving 27 patients

“Double-hit” precipitates fulminant cardiac dysfunction in a child with homozygous CAP2 variant: a case report

Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study